Genetic Engineering & Biotechnology News

OCT1 2012

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/83770

Contents of this Issue

Navigation

Page 68 of 89

ADVERTORIAL Corporate Capabilities Charles River F or more than 60 years, Charles River has been helping our glob- al partners accelerate drug discovery and develop- ment by providing them with high-quality research mod- els, preclinical services, pro- cess manufacturing support, and clinical trial support ser- vices. Our offerings span the entire drug development pro- cess, from discovery through market approval, providing our clients a seamless partner- ship throughout. From the global standard- ization of our research mod- els, to the high standards we set for our professional team and our state-of-the-art facili- ties and technologies, we can customize our products and services to meet clients' specific research needs. With facili- ties around the world, Charles River is the ideal partner for moving a compound through development in a rational, cost-effective, and timely manner. Markets Served Charles River 251 Ballardvale Street Wilmington, MA 01887 Phone 877.CRIVER.1 Website www.criver.com Date Founded 1947 Number of Employees ~7,500 With more than 60 facilities in 16 countries, Charles River partners with leading pharmaceu- tical, biotechnology, government, and academic organizations around the world to provide products and services that span all stages of drug discovery and development. Our team of experts understands, and ul- timately can help our customers comply with, complex and varying international scientific regulations. Capabilities Our offerings are continually expanding based on the changing needs of our customers, and our portfolio reaches from the discovery of new compounds and preclinical pharmacologi- cal and safety studies to clinical trials support. Charles River also provides biopharmaceutical testing and manufacturing services to help our partners efficiently navigate the complex process of developing a biologic. Biopharmaceutical Services Charles River Biopharmaceutical Services (BPS) delivers client-focused solutions for the specific testing and manufacturing requirements of your biologic. We provide tailored global test- ing and manufacturing services to help acceler- ate drug development from concept to product release. BPS has the capabilities to address the needs of companies based anywhere in the world. Our BPS facilities in the U.S., U.K., Ireland, and Ger- many are part of a global scientific network, of- fering products and services that span the entire drug development process. Furthermore, BPS has agents in Australia, Japan, India, Korea, Singapore, and Taiwan to support our clients around the world. We aim to make it easy to work with us, and to that end, BPS provides you with more flexibil- ity, experience and expertise in multiple regula- tory environments to accelerate the development of your biologic, enabling you to get your prod- uct to market faster. BPS follows international regulatory guide- lines for testing and clinical-scale manufacturing of biologics. The assays provided range from cell characterization and process-validation studies through to stability and product-release testing. Manufacturing services include cell banking, storage, fill and finish, and viral vaccine and an- Genetic Engineering & Biotechnology News | genengnews.com | October 1, 2012 | 67 tisera production. Areas of expertise include: UÊ Cell banking and characterization UÊ Product characterization UÊ Process characterization (residual testing) UÊ Vaccines and cell therapy UÊ Viral clearance and TSE studies UÊ Lot release testing UÊ Stability testing UÊ In vivo biosafety and potency testing UÊ Discovery and development UÊ Polyclonal antisera production We have recently expanded our Ireland fa- cility to offer biosafety level 2(BSL-2) in vivo challenge studies (bacterial & viral). The new self-contained, high-biosecurity shower-in unit includes 12 new animal rooms, allowing for in- creased capacity ideal for long-term vaccine and immunogenicity. Q Helping Our Global Partners Accelerate Drug Discovery and Development for More than 60 Years

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - OCT1 2012